

Short Conceptual Overview

Origin and function of embryonic Sertoli cells

Francisco Barrionuevo*, Miguel Burgos and Rafael Jiménez

Departamento de Genética e Instituto de Biotecnología, Universidad de Granada, Lab 127, Centro de Investigación Biomédica, Avenida del Conocimiento s/n, 18100 Armilla, Granada, Spain

* Corresponding author
e-mail: fjbarrio@ugr.es

Abstract

In the adult testis, Sertoli cells (SCs) are the epithelial supporting cells of the seminiferous tubules that provide germ cells (GCs) with the required nutrients and structural and regulatory support to complete spermatogenesis. SCs also form the blood-testis barrier, phagocytose apoptotic spermatocytes and cell debris derived from spermiogenesis, and produce and secrete numerous paracrine and endocrine signals involved in different regulatory processes. In addition to their essential functions in the adult testis, SCs play a pivotal role during testis development. They are the first cells to differentiate in the embryonic XY gonadal primordium and are involved in the regulation of testis-specific differentiation processes, such as prevention of GC entry into meiosis, Leydig and peritubular myoid cell differentiation, and regression of the Müllerian duct, the anlagen of the uterus, oviducts, and the upper part of the vagina. Expression of the Y-linked gene *SRY* in pre-SCs initiates a genetic cascade that leads to SC differentiation and subsequently to testis development. Since the identification of the *SRY* gene, many Sertoli-specific transcription factors and signals underlying the molecular mechanisms of early testis differentiation have been identified. Here, we review the state of the art of the molecular interactions that commit the supporting cell lineage of the gonadal primordium to differentiate as SCs and the subsequent Sertoli-specific signaling pathways involved in early testis differentiation.

Keywords: embryonic Sertoli cell; embryonic testis function; SOX9; SRY; testis differentiation.

Introduction

Sertoli cells (SCs) represent the somatic component of the germinative epithelium of the testis (1), and their presence is crucial for both testicular development and function. The other component of the germinative epithelium, located inside

the seminiferous tubules, is the germ cells (GCs), which, in the adult testis, are spermatogonia, meiotic, and postmeiotic cells. SCs are epithelial in nature, with the basal pole oriented toward the peritubular myoid cells (PMCs) that surround the seminiferous tubule and the apical pole oriented toward the tubular lumen. Their cytological structure is quite complex, with a generally basal nucleus and a very large and morphologically changing cytoplasm that accommodates the spaces between the neighboring GCs. In the adult testis, SCs establish specialized inter-Sertolian junctions near the basal lamina of the seminiferous tubules, which form a blood-testis barrier [see (2) for a review on SC biology].

According to the classical view, SCs are sustentacular and nurse cells that provide GCs with the required nutrients and structural support. Now, it is known that these cells have many other important functions, both structural and regulatory. Structurally, the blood-testis barrier defines two compartments in the germinative epithelium: adluminal and basal. Spermatogonia are peripherally located in the basal compartment, and once they enter meiosis, SCs actively transport the newly formed primary spermatocytes toward the adluminal compartment, from which the haploid meiotic products are finally released in the tubular lumen. This implies that the junctional system established between SCs and GCs must be very complex and dynamic to permit the basal-to-apical migration of the GCs through the interstitial spaces between adjacent SCs (3). SCs also participate, together with PMCs, in the formation of the basal lamina of the seminiferous tubules. Furthermore, the blood-testis barrier maintains meiotic and postmeiotic GCs isolated from the vascular environment, thus precluding the formation of antisperm antibodies. Another relevant function of SCs is to phagocytose apoptotic spermatocytes and cellular debris derived from spermiogenesis, the differentiation of the meiotic products into sperm (4, 5).

SCs are the main targets of the hormones regulating the spermatogenic function in the seminiferous tubules. They receive hormonal signals that regulate reproduction, including follicle-stimulating hormone (FSH), testosterone, and triiodothyronine (T_3) (6), establishing regulatory cross-talk with GCs, thus controlling the timing of spermatogenesis. The regulatory action of SCs is exerted mainly through the production and secretion of numerous paracrine and endocrine signals, including inhibins and activins, which contribute to control the secretion of FSH by the hypophysis [reviewed by (7)]; androgen-binding protein (ABP), thought to be required for maintaining high levels of testosterone inside the seminiferous tubules (8); glial cell line-derived neurotrophic factor, which controls the proliferation of the spermatogonial stem cells, thus regulating their renewal to maintain the pool

of testicular GCs [reviewed by (9)]; 17 β -estradiol, which regulates spermatogenesis (10); a variety of growth factors, including nerve growth factors, fibroblast growth factors (FGF), insulin-like growth factors, and transforming growth factors (TGF), which establish profuse SC-GC communication [reviewed in (11)]; Ets-related molecule (ERM), required for transcriptional control of the spermatogonial stem cell niche (12), among others.

It is thus evident that SCs play several pivotal roles in the adult testis, but their functions are not less important in the developing testis. The present article seeks to review the ontogenic origin, differentiation, and function of the early embryonic SCs, thus showing that SCs direct crucial events of testis organogenesis.

Ontogenic origin and differentiation of SCs

The differentiation of SCs is the key event in testis development, a process that has been well studied in a few mammalian species. In the sexually undifferentiated mouse embryo, genital ridges appear in the ventromedial surface of the mesonephroi, between 10.5 and 11.5 days postcoitum (dpc), as a consequence of proliferation of the coelomic epithelium. These genital ridges give rise to the bipotential gonads, which are equally formed on both males and females. In addition to the somatic cells derived from the coelomic epithelium, the bipotential gonad also contains primordial germ cells (PGCs), which have an extragonadal origin, as they migrate into the

gonad from a reduced population of epiblast cells in the extraembryonic mesoderm through the dorsal mesentery (13, 14). Somatic cells and PGCs in the bipotential gonad form a gonadal blastema, where gonadal (sexual) cords are formed in both sexes in most species, including the rat (15), but not in the mouse [reviewed in (16)] (Figure 1).

Testis development begins with three main events in most mammals studied: differentiation of pre-SCs, in which the sex-determining genes are expressed (see below), into SCs; migration of endothelial cells from the adjacent mesonephros; formation of the testicular cords composed of SCs and PGCs (Figure 1). Using transgenic mice expressing the reporter gene *EGFP* (enhanced green fluorescent protein) under the control of the *Sry* promoter, Albrecht and Eicher (17) showed that pre-SCs are mesenchymal in nature, implying that they must undergo a mesenchymal-to-epithelial cell-type transition to differentiate as SCs. For this, they have to polarize by accumulating extracellular matrix proteins, such as collagen type IV, laminin, fibronectin, and heparin sulfate proteoglycan in the basal pole [reviewed in (18)]. As they differentiate, SCs and PGCs aggregate to form the testis cords, which involves a major remodeling of their cell junction system, a process in which integrin subunits as well as lectins are known to be involved (19, 20).

It is well known that cell migration from the mesonephros to the gonad is a crucial event in gonad differentiation, as it is exclusive of the XY gonad at early stages of gonad development (21). It depends on the presence of the *Sry* gene (22) and is needed for the formation of both the testis cords (23) and




Figure 1 An overview of early SC and testis differentiation.

Shortly after the gonadal ridge arises as a thickening of the coelomic epithelium of the mesonephros (A), migrating PGCs colonize the gonad and form, together with the somatic cells, the gonadal blastema (B). Shortly later, a group of somatic cells, the pre-SCs express *SRY* in the bipotential gonad and undergo a mesenchyme-to-epithelial transition, aggregate, and form the testis cords, which include the GCs (C). *SRY* expression also induces endothelial cell migration from the mesonephros and the development of an extensive vasculature including the coelomic vessel (CV). After testis cord formation, other testicular cell types differentiate, such as LCs and PMCs (D).

the testis-specific vascular system (24). Although, it is clear that the chemoattractant signal that induces mesonephric cell migration is secreted by cells located within the gonad (21, 25, 26) and that platelet-derived growth factor (PDGF) signaling is involved in the process (27), there is, however, some controversy concerning the nature of the mesonephric cells that migrate into the gonad. Endothelial cells and precursors of both PMCs and Leydig cells (LCs) have been proposed to comprise the population of mesonephric migrating cells (23, 28, 29). Some studies have shown that the mesonephros contribute with LC precursors to the developing testis (28, 29), but others support the idea that LC precursors are already present in the gonad by 11.5 dpc, when cell migration takes place, and that they are not derived from the mesonephros after this stage (27). Similarly, several experiments have strongly suggested that PMCs could derive from precursor cells migrating from the mesonephros (21, 23, 25, 30). However, more recent studies (31) have shown that cells expressing α Sma-EYFP (in these cells, the fluorescent reporter gene *EYFP* is expressed under the control of the promoter of α Sma, a typical molecular marker for PMCs) do not migrate into the gonad during the critical window of sex determination, which strongly suggests that PMC precursors do not derive from mesonephric cells. Hence, endothelial cells are the only cell type known to date to migrate from the mesonephros to the gonad (31).

In the mouse, the three main events of testis differentiation (SC differentiation, testis cord formation, and mesonephric cell migration) occur almost simultaneously between 11.5 and 12.5 dpc (21, 23, 25, 26). Also, both the morphological and the functional differentiation of mouse SCs are simultaneous [the latter evidenced mainly by the early production of anti-Müllerian hormone (AMH)], which makes it difficult to distinguish between these two aspects of SC differentiation. However, studies performed in the Iberian mole, *Talpa occidentalis* (32), have shown a very early expression of both *SOX9* and *AMH* genes (the two most evident SCs markers), coinciding with the onset of the formation of the genital ridge at 15 dpc (stage s4b), 3 days before the formation of the testis cords at 18 dpc (s5b stage), when mesonephric cell migration occurs in this species (33). Hence, currently available data indicate that the functional differentiation of SCs, as a consequence of the activation of the gene cascade initiated by *SRY* that includes *SOX9* and *AMH*, is a prerequisite for the occurrence of further events of testis differentiation, including their morphological differentiation and the mesonephric cell migration. Testis cord formation appears to require the presence both of SCs and of some unknown cell precursors migrating from the mesonephros.

Long-standing controversy surrounds the ontogenic origin of SCs. The hypothesis that the mesonephric tubule cells dedifferentiate from the epithelial structure at the mesonephros-gonad border, migrate into the gonad, and contribute to the SC population has been supported by several authors (34–36). On the other hand, the fact that AMH can be detected in the medium when 11.5-dpc isolated gonads are cultured (30), just when migration starts, clearly suggests that SCs are present in the gonad prior to mesonephric cell migration [reviewed in (37)]. Using the lipophilic dye, *DiI*, as a living cell marker

for coelomic epithelium cells in cell tracing experiments, Karl and Capel (38) showed that SCs derive from a portion of coelomic epithelium cells that proliferate and migrate into the gonad during the early stages of gonadal development, whereas other coelomic epithelium cells colonizing the gonad at later stages become testis interstitial cells. Albrecht and Eicher's (17) experiment with transgenic mice showed that *Sry* expression takes place in the SCs and that both SCs and granulosa (follicle) cells share a common ontogenic origin.

Genetic control of SC differentiation: the basis of mammalian sex determination

Upstream of SRY

Several genes are known to be expressed in pre-SCs, including *WT1*, *SF1*, *GATA4*, *FOG2*, and *FGF9*, before sex differentiation, which is induced by the activation of the mammalian-specific, master regulatory testis-determining gene, *SRY* (sex determining region of chromosome Y) in pre-SCs. *SRY* initiates a cell-autonomous cascade of gene regulation leading to SC differentiation and subsequent testis development (39–41). Little is known about the molecular mechanisms underlying *SRY* activation in the XY bipotential gonad, but several transcription factors are known to be involved in the regulation of this gene. One of them is *WT1* (Wilms tumor suppressor gene 1), which is expressed in the genital ridge, in the coelomic epithelium, and in the sex cords of the gonadal primordium in both sexes, as well as in the adjacent mesonephros (42). Several human syndromes reveal the importance of *WT1* in early gonadal development, such as the Wilms tumor-aniridia-mental retardation-genitourinary tract abnormalities syndrome (43), in which patients show anomalies in the genitourinary tract; the Denys-Drash syndrome, a condition associated to male pseudohermaphroditism (44); and the Frasier syndrome, which involves XY sex reversal and glomerulonephropathy (45). Accordingly, *Wt1*^{-/-} embryos initially form a gonadal primordium, but subsequently, it degenerates by increased apoptosis (46). *WT1* possesses an alternative splice site that results in the insertion (+KTS) or exclusion (-KTS) of the three amino acids Lys-Thr-Ser (47). Mice of any sex with a null mutation of the -KTS isoform had poorly differentiated small gonads, indicating that this isoform is necessary for cell survival in the gonadal primordium. In contrast, those with a null mutation of the +KTS isoform showed XY sex reversal with reduced levels of *Sry* expression, indicating that this splice variant is involved in *Sry* regulation (47). However, the *in vitro* data are controversial, as one study showed that only the -KTS variant of *WT1* can activate the promoter of the human *SRY* (48), whereas other results revealed that both *WT1* isoforms may interact with *GATA4* and synergistically activate the *SRY* promoter (49). Thus, although *WT1* is a good candidate gene for regulating *SRY*, it is not yet clear whether *SRY* is a direct or an indirect transcriptional target of *WT1*. In addition to *WT1*, other factors could participate in the regulation of *SRY* expression, including the *GATA* zinc finger transcription factor 4 (*GATA4*) and its cofactor *FOG2*

(friend of GATA 2), which are expressed in somatic cells of both XX and XY genital ridges (50, 51). *Fog2*^{-/-} embryos as well as embryos homozygous for a *Gata4* mutation that abrogates the interaction of GATA4 with FOG cofactors exhibit a blockage in SC differentiation. In addition, *Sry* transcripts levels are reduced in *Fog2*^{-/-} testes (51). Also, the insulin receptor family is expressed in the urogenital ridge and is necessary for *Sry* expression (52). Furthermore, studies made with knockout mice have shown that other genes, such as *Sfl* (*Nr5a1* gene) (53), *Emx2* (54), and *Lhx9* (55), contribute to the proliferation of the genital ridge and the formation of the indifferent gonad (Figure 2). In conclusion, despite that many *in vitro* studies have been performed to identify new molecular interactions among these factors that may be involved in the subsequent activation or repression of *SRY*, the molecular mechanisms underlying the regulation of this gene are still poorly understood.

Downstream of SRY

Once *SRY* is activated, pre-SCs are committed to differentiate into SCs. Although many studies have found a number of molecules acting downstream of *SRY*, *SOX9* is currently its only known direct target. *SOX9* is expressed in the gonadal ridge of both sexes, becoming upregulated in the male but not in the female gonad after the critical stage of sex determination (56). Cases of XY sex reversal associated with *SOX9* mutations have been described both in humans (57, 58) and in mice (59, 60). In addition, ectopic activation of *Sox9* in the bipotential gonad causes XX sex reversal (61, 62). More recently, it has been shown that *SRY* binds to a gonad-specific enhancer of the murine *Sox9*, as does SF1, and a model in which SF1 and *SRY* cooperatively upregulate *SOX9* has been proposed (63). According to this model, *SOX9* also binds to the same enhancer and cooperates to maintain its own expression in an autoregulatory loop. Another protein necessary for SC differentiation is the FGF9, as *Fgf9*^{-/-} mice exhibit XY reversal (64). This gene is initially expressed in the gonads of both sexes, but becomes male-specific once *SRY* is activated (65). By establishing a feed-forward loop with *SOX9*, *FGF9*

antagonizes ovary-promoting processes, such as the WNT signaling. *WNT4* (wingless-related MMTV integration site 4 gene) and *RSPO1* (R-spondin 1) are two molecules involved in the canonical WNT signaling pathway, its expression in the urogenital ridge becoming female-specific after the sex-determination stage (66, 67). Mutations in any of these two molecules cause XY sex reversal (67–70). Furthermore, ectopic activation of the WNT signaling pathway in the XY gonad leads to ovary development (71), indicating that the WNT signaling pathway actively promotes female gonadal differentiation. Thus, FGF9 and WNT act as opposing signals during sex determination, so that during testis differentiation *SRY* activates *SOX9*, which initiates a feed-forward loop together with FGF9, which in turn upregulates *FGF9* and represses WNT signals, leading to SC differentiation (66).

Embryonic SC functions

Once SCs differentiate, they orchestrate the development of the bipotential gonad into the testis. SC function is necessary for the correct development of the testis cords (structures that transform into the seminiferous tubules after puberty), the differentiation of GCs into sperm, the differentiation of the somatic LCs and PMCs, and the proper regression of the Müllerian ducts (the embryonic structures that differentiate into the female secondary sex organs).

Induction of testis cord formation

After the time of sex determination, SCs actively proliferate until shortly after birth, resulting in an expansion of the number of testis cords. Later, SCs proliferation and testis cord expansion progressively declines, and at puberty, SCs proliferation is not detectable (72). The cell-autonomous action of *Sry* seems to be the only mechanism of SC differentiation (73), and mitotic proliferation appears to be the only mechanism underlying SCs expansion (65, 74). However, a re-evaluation of the XX-XY chimeric mice initially studied by Burgoyne et al. (73) showed the proportion of XX/XY cells to be about




Figure 2 Genetic control of SC differentiation.

Several genes that contribute to the proliferation and formation of the indifferent gonad are expressed in the bipotential gonad, including *WT1* (+KTS), *GATA/FOG2*, *SF1*, *IRF* family, *ERMx2*, and *LHX9*; some are involved in the activation of *SRY*. At the testis determination stage, *SRY* and SF1 initially upregulate *Sox9* expression. Then *SOX9* autoregulates *Sox9* together with SF1. At the same time, *SOX9* establishes a positive feedback loop via FGF9 signaling leading to SC differentiation. The *SOX9/FGF9* loop leads to downregulation of the WNT signaling pathway, thus inhibiting the female pathway.

the expression of pluripotent cell markers, such as *OCT4* (84). Several observations lead to the hypothesis that PGCs are programmed to enter meiosis and initiate oogenesis through the action of a meiosis-promoting substance, whereas other studies suggest the existence of a male meiosis-preventing factor [reviewed in (85)]. Retinoic acid (RA) has been proposed as a meiotic-promoting substance (86, 87). The *STRA8* gene (stimulated by retinoic acid gene 8) encodes a factor required for PGCs to enter meiosis in both sexes (88). *Stra8* is expressed in PGCs in the mouse embryonic ovaries around the time of meiosis onset, but not in embryonic testes, as male meiosis does not initiate until puberty (89). *CYP26B1* encodes a RA-metabolizing cytochrome P450 enzyme that is expressed in SCs. PGCs of mouse testes lacking *Cyp26b1* enter meiosis prematurely, although they arrest in pachytene and undergo apoptosis. In contrast, ovarian GCs appear unaffected by the lack of *Cyp26b1* (90). These two molecules interact with RA signaling, as RA has been shown to activate the expression of *Stra8* in embryonic carcinoma cells and in stem cells in culture (91, 92), and CYP26B1 catabolizes RA to more polar metabolites for excretion, so that those gonadal regions expressing *Cyp26b1* lack detectable levels of RA (93, 94). Also, it was shown that during gonadal development, RA is synthesized in the mesonephros of both males and females, and it apparently diffuses into the adjacent gonad. According to these findings, a consistent hypothesis has been proposed on the control of meiosis onset in male and female gonads: in ovaries, diffused RA from the mesonephros would activate *Stra8*, which in turns would induce PGCs to enter meiosis thus initiating oocyte differentiation. In contrast, in the testes, RA would be catabolized by CYP26B1, thus preventing *Stra8* upregulation and meiosis entry (86, 87). However, a recent study has questioned this model (95). Analysis of mice ablated for retinaldehyde dehydrogenase 2 (*Raldh2*), a gene that controls RA synthesis, revealed that activation of *Stra8* expression in the fetal ovary does not require RA signaling, as this gene can be expressed in the absence of physiologically detectable levels of RA. It was also shown that when *Cyp26b1* was inactivated in *Raldh2* mutant testes, *Stra8* was induced in a RA-independent manner, but only when the mesonephros remained attached. The authors propose that CYP26B1 prevents the onset of meiosis by metabolizing a mesonephric substrate, other than RA, that controls *Stra8* expression. A second SC factor involved in this process is *FGF9*. In XY but not XX *Fgf9* null mouse embryos, most GCs die shortly after the sex determination stage, and some of the surviving XY GCs express meiotic markers (64). Further analysis of the *Fgf9* null testes showed that FGF9 acts directly on PGCs to prevent their entry into meiosis, maintain pluripotency, and actively promote the male fate (96). These authors have proposed that FGF9 signaling antagonizes RA signaling in SCs to determine male GC fate commitment. However, according to the new data reported by Kumar et al. (95), rather than RA, FGF9 would antagonize a different meiosis-promoting substance. Two additional molecules involved in the WNT signaling pathway, which are necessary for XX but not XY GC survival, are WNT4 and RSP01. Ovaries of both *Wnt4*^{-/-} and *Rspo1*^{-/-} mutant mice contain only a few

degenerating oocytes at birth (68, 70), and the expression of *Cyp26b1* in these embryonic mutant ovaries is upregulated (69, 97). Accordingly, if it is considered that the stabilization of β -catenin, the intracellular mediator of the WNT signaling, in somatic cells of XY gonads results in the activation of the ovarian pathway in GCs (71) and when SC function is compromised during testis development, WNT signaling is upregulated (79, 81), then it can be concluded that WNT signaling may promote female GC fate, whereas SC function would antagonize this process (Figure 3).

Induction of LCs and PMCs differentiation

SCs are also involved in promoting the differentiation of other somatic cell types of the testis, including LCs and PMCs. At least two LC populations, fetal Leydig cells (FLCs) and adult Leydig cells (ALCs), arise sequentially during testis development and, although all LCs have androgen biosynthetic capacity, FLC and ALC populations are different in morphology and gene expression profiles (98). In mice, FLCs are first visible in the interstitial compartment of the testis, the space between the testis cords, at around 24 h after SC differentiation (99). The FLC population expands enormously in the following two days, although this increase in number is not a result of cell proliferation during this period, but rather is a consequence of differentiation of interstitial mesenchymal cells migrated either from the coelomic epithelium domain or from the mesonephros. It is assumed that the differentiation of FLCs depends on SC function, although little is known about the specific signals involved in this process. One of these signaling molecules is desert hedgehog (DHH), one of the three mammalian hedgehog family ligands, which is expressed in SCs. FLCs express the gene encoding the hedgehog receptor patched1 (PTCH1), and analysis of *Dhh* knockout testes revealed that differentiation of FLCs was severely impaired (100). This aberrant FLC cell differentiation was not the result of either a failure of the mesonephric cell migration or defective cell proliferation or survival. Rather, it seems to be the consequence of a defective upregulation of *Sfl* expression in the precursor cells expressing *Ptch1*, indicating that *Sfl* could be an intracellular target of the *Dhh/Ptch1* pathway. However, in *Dhh*^{-/-}; *Sfl*^{+/-} compound mutant mice, FLCs failed to differentiate, with the subsequent absence of fetal testosterone, which results in defective masculinization (secondary sex reversal) (101). These data indicate that the combined function of *Dhh* and *Sfl* is required for LC development. Another molecule known to be involved in FLC differentiation is the PDGF receptor α (PDGFR α), as testes in *Pdgfra*^{-/-} mutant mice have reduced or absent FLCs (27). There are three known ligands for PDGFR α , PDGF-A, PDGF-B, and PDGF-C, but only the *Pdgf-A* gene is expressed in SCs (102), suggesting that SCs could modulate FLC differentiation through the action of this ligand. Indeed, deletion of *Pdgf-A* induces defects in the development of ALCs, but the number of FLCs was apparently normal (103). Thus, it is not clear whether *Pdgf-A* has an important role in the differentiation of FLCs. There are also other molecular signaling pathways affecting the differentiation of FLCs, the receptors of which are

expressed in this cell type, but it is not known whether SCs are the source of the ligand activating these pathways. This is the case for the TGF β superfamily. Expression of type I and type II TGF β receptors, as well as of betaglycan (Tg β r3), a coreceptor for TGF β superfamily ligands, has been detected in LCs (104, 105). The loss of Tg β r3 expression in fetal mouse testes induces alterations of testis cord development and compromised FLC function. By contrast, SC function seems to be normal until two days after FLC differentiation, suggesting that disruption in TGF β signaling in FLCs, rather than defective SC function, is the origin of the anomalies seen in the FLCs of testes from Tg β r3^{-/-} mutant mice (106). Two of the three mammalian TGF β ligands, TGF β 1 and TGF β 2, are expressed in SCs (107), and knockout mice for every factor exhibited defective testes (108). However, none of these studies evidenced any association between the defective production of such ligands by SCs and the abnormal development of FLCs.

PMCs form a single layer of flattened cells surrounding the testis cords. Little is known about the molecular mechanisms underlying the initial differentiation of this cell type, although there is evidence that signals from SCs have an important role in this process. The best known example is again DHH signaling: the hedgehog receptor, *Ptch1*, is expressed in PMCs, and the lack of *Dhh* in murine SCs leads to testes with PMC defects (109). FLC and/or PMC differentiation in the absence of SCs have been observed in some normal and pathologic cases of XX sex reversal [(110, 111), among others], but this is a quite rare trait. A convincing explanation for these cases is the ectopic activation of a Sertoli-specific signaling pathway in XX gonadal cells. Accordingly, when the hedgehog signaling is ectopically activated in the mouse fetal ovary, FLCs differentiate in the absence of SCs (112) (Figure 3).

Induction of Müllerian duct regression during male development

A hormone secreted by early SCs is responsible for inducing the degeneration in the male mesonephroi of the Müllerian ducts, the precursors of the female secondary sexual organs (113). This factor is the Anti-Müllerian Hormone (AMH), a signal molecule belonging to the TGF β superfamily. AMH binds to its type II receptor (AMHR2) in the Müllerian duct mesenchyme, leading to the regression of the Müllerian duct mesoepithelium (113–115). Male mice lacking either *Amh* or *Amhr2* genes develop as pseudohermaphrodites, exhibiting internally a complete male reproductive tract as well as a uterus and oviducts. Both *Amh*^{-/-} and *Amhr2*^{-/-} mutant male mice produce sperm, but most are infertile because their female reproductive organs block the sperm transfer into females (114, 115). Regulation of AMH expression depends on several Sertoli transcription factors, including SOX9, SOX8, SF1, and WT1. When *Sox9* is inactivated before the sex determination stage, *Amh* expression is not initiated, and Müllerian duct regression does not take place (59, 60). *In vivo* and *in vitro* studies revealed that SOX9 acts through a SOX binding site within the AMH promoter (116, 117). SOX8 also activates the AMH promoter in the same manner, but

less efficiently (118). Null mutant mice for *Sox8* or mice in which *Sox9* was ablated shortly after *Amh* expression is initiated produce sufficient levels of *Amh* transcripts to induce the regression of the Müllerian ducts (81, 119). By contrast, when both genes are deleted simultaneously shortly after *Amh* expression begins, lower levels of *Amh* expression and partial persistence of Müllerian duct derivatives result (81). These findings indicate that *Sox9* is necessary for the initiation of *Amh* expression, but redundancy between *Sox9* and *Sox8* is necessary for the maintenance of *Amh* expression. There is also an SF1 binding site in the AMH promoter, a factor that interacts together with SOX9 to synergistically activate AMH expression (Figure 3) (116, 117). *Wt1* ablation after the sex determination stage results in the complete absence of SOX9, SOX8, and AMH proteins and adult *Wt1* mutant males maintain Müllerian duct derivatives, such as a residual uterus (79), indicating that *Wt1* regulates the maintenance of *Amh* expression partly through the control of *Sox9* and *Sox8* expression and partly *via* additional unknown routes.

Acknowledgments

The authors would like to thank David Nesbitt for revising the English style of the manuscript. This work was supported by the Spanish Ministry of Investigation, Science and Innovation through grant no. CGL2008-00928/BOS.

References

1. Ebner V. Zur Spermatogenese bei den Säugethieren. Arch Mikrosk Anat 1888; 31: 236–92.
2. Skinner MK, Griswold MD. Sertoli cell biology. San Diego, CA: Elsevier Academic Press, 2005.
3. Cheng CY, Mruk DD. Cell junction dynamics in the testis: Sertoli-germ cell interactions and male contraceptive development. Physiol Rev 2002; 82: 825–74.
4. Carr I, Clegg EJ, Meek GA. Sertoli cells as phagocytes: an electron microscopic study. J Anat 1968; 102: 501–9.
5. Shiratsuchi A, Kawasaki Y, Ikemoto M, Arai H, Nakanishi Y. Role of class B scavenger receptor type I in phagocytosis of apoptotic rat spermatogenic cells by Sertoli cells. J Biol Chem 1999; 274: 5901–8.
6. Silva FRMB, Leite LD, Wassermann GF. Rapid signal transduction in Sertoli cells. Eur J Endocrinol 2002; 147: 425–33.
7. de Kretser DM, Buzzard JJ, Okuma Y, O'Connor AE, Hayashi T, Lin S-Y, Morrison JR, Loveland KL, Hedger MP. The role of activin, follistatin and inhibin in testicular physiology. Mol Cell Endocrinol 2004; 225: 57–64.
8. Dohle GR, Smit M, Weber RFA. Androgens and male fertility. World J Urol 2003; 21: 341–5.
9. Hofmann M-C. Gdnf signaling pathways within the mammalian spermatogonial stem cell niche. Mol Cell Endocrinol 2008; 288: 95–103.
10. Dorrington JH, Armstrong DT. Follicle-stimulating hormone stimulates estradiol-17beta synthesis in cultured Sertoli cells. Proc Natl Acad Sci USA 1975; 72: 2677–81.
11. Schlatt S, Meinhardt A, Nieschlag E. Paracrine regulation of cellular interactions in the testis: factors in search of a function. Eur J Endocrinol 1997; 137: 107–17.

12. Chen C, Ouyang W, Grigura V, Zhou Q, Carnes K, Lim H, Zhao G-Q, Arber S, Kurpios N, Murphy TL, Cheng AM, Hassell JA, Chandrashekar V, Hofmann M-C, Hess RA, Murphy KM. ERM is required for transcriptional control of the spermatogonial stem cell niche. *Nature* 2005; 436: 1030–4.
13. Tam PP, Snow MH. Proliferation and migration of primordial germ cells during compensatory growth in mouse embryos. *J Embryol Exp Morphol* 1981; 64: 133–47.
14. McLaren A. The fate of germ cells in the testis of fetal sex-reversed mice. *J Reprod Fertil* 1981; 61: 461–7.
15. Merchant-Larios H. The onset of testicular differentiation in the rat: an ultrastructural study. *Am J Anat* 1976; 145: 319–29.
16. Jiménez R. Ovarian organogenesis in mammals: mice cannot tell us everything. *Sex Dev* 2009; 3: 291–301.
17. Albrecht KH, Eicher EM. Evidence that Sry is expressed in pre-Sertoli cells and Sertoli and granulosa cells have a common precursor. *Dev Biol* 2001; 240: 92–107.
18. Cupp A, Skinner M. Embryonic Sertoli cell differentiation. In: Skinner MK, Griswold MD, editors. *Sertoli cell biology*. San Diego, CA: Elsevier Academic Press, 2005: 43–70.
19. Fröjdman K, Malmi R, Pelliniemi LJ. Lectin-binding carbohydrates in sexual differentiation of rat male and female gonads. *Histochemistry* 1992; 97: 469–77.
20. Fröjdman K, Pelliniemi LJ. Differential distribution of the alpha 6 subunit of integrins in the development and sexual differentiation of the mouse testis. *Differentiation* 1994; 57: 21–9.
21. Martineau J, Nordqvist K, Tilmann C, Lovell-Badge R, Capel B. Male-specific cell migration into the developing gonad. *Curr Biol* 1997; 7: 958–68.
22. Capel B, Albrecht KH, Washburn LL, Eicher EM. Migration of mesonephric cells into the mammalian gonad depends on Sry. *Mech Dev* 1999; 84: 127–31.
23. Buehr M, Gu S, McLaren A. Mesonephric contribution to testis differentiation in the fetal mouse. *Development* 1993; 117: 273–81.
24. Coveney D, Ross AJ, Slone JD, Capel B. A microarray analysis of the XX Wnt4 mutant gonad targeted at the identification of genes involved in testis vascular differentiation. *Gene Expr Patterns* 2008; 8: 529–37.
25. Tilmann C, Capel B. Mesonephric cell migration induces testis cord formation and Sertoli cell differentiation in the mammalian gonad. *Development* 1999; 126: 2883–90.
26. Albrecht KH, Capel B, Washburn LL, Eicher EM. Defective mesonephric cell migration is associated with abnormal testis cord development in C57BL/6J XY (Mus domesticus) mice. *Dev Biol* 2000; 225: 26–36.
27. Brennan J, Tilmann C, Capel B. Pdgfr-alpha mediates testis cord organization and fetal Leydig cell development in the XY gonad. *Genes Dev* 2003; 17: 800–10.
28. Nishino K, Yamanouchi K, Naito K, Tojo H. Characterization of mesonephric cells that migrate into the XY gonad during testis differentiation. *Exp Cell Res* 2001; 267: 225–32.
29. Merchant-Larios H, Moreno-Mendoza N. Mesonephric stromal cells differentiate into Leydig cells in the mouse fetal testis. *Exp Cell Res* 1998; 244: 230–8.
30. Merchant-Larios H, Moreno-Mendoza N, Buehr M. The role of the mesonephros in cell differentiation and morphogenesis of the mouse fetal testis. *Int J Dev Biol* 1993; 37: 407–15.
31. Cool J, Carmona FD, Szucsik JC, Capel B. Peritubular myoid cells are not the migrating population required for testis cord formation in the XY gonad. *Sex Dev* 2008; 2: 128–33.
32. Carmona FD, Lupiáñez DG, Martín J-E, Burgos M, Jiménez R, Zurita F. The spatio-temporal pattern of testis organogenesis in mammals – insights from the mole. *Int J Dev Biol* 2009; 53: 1035–44.
33. Barrionuevo FJ, Zurita F, Burgos M, Jiménez R. Testis-like development of gonads in female moles. New insights on mammalian gonad organogenesis. *Dev Biol* 2004; 268: 39–52.
34. Wartenberg H. Development of the early human ovary and role of the mesonephros in the differentiation of the cortex. *Anat Embryol* 1982; 165: 253–80.
35. Zamboni L, Upadhyay S. The contribution of the mesonephros to the development of the sheep fetal testis. *Am J Anat* 1982; 165: 339–56.
36. Satoh M. The histogenesis of the gonad in rat embryos. *J Anat* 1985; 143: 17–37.
37. Byskov AG. Differentiation of mammalian embryonic gonad. *Physiol Rev* 1986; 66: 71–117.
38. Karl J, Capel B. Sertoli cells of the mouse testis originate from the coelomic epithelium. *Dev Biol* 1998; 203: 323–33.
39. Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, Foster JW, Frischauf AM, Lovell-Badge R, Goodfellow PN. A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. *Nature* 1990; 346: 240–4.
40. Gubbay J, Collignon J, Koopman P, Capel B, Economou A, Münsterberg A, Vivian N, Goodfellow P, Lovell-Badge R. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. *Nature* 1990; 346: 245–50.
41. Koopman P, Gubbay J, Vivian N, Goodfellow P, Lovell-Badge R. Male development of chromosomally female mice transgenic for Sry. *Nature* 1991; 351: 117–21.
42. Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterpacht A, Zabel B. Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. *Development* 1993; 119: 1329–41.
43. Baird PN, Groves N, Haber DA, Housman DE, Cowell JK. Identification of mutations in the WT1 gene in tumours from patients with the WAGR syndrome. *Oncogene* 1992; 7: 2141–9.
44. Little M, Holmes G, Bickmore W, van Heyningen V, Hastie N, Wainwright B. DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. *Hum Mol Genet* 1995; 4: 351–8.
45. Barboux S, Niaudet P, Gubler MC, Grünfeld JP, Jaubert F, Kuttann F, Fékété CN, Souleyreau-Therville N, Thibaud E, Fellous M, McElreavey K. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. *Nat Genet* 1997; 17: 467–70.
46. Kreidberg JA, Sariola H, Loring JM, Maeda M, Pelletier J, Housman D, Jaenisch R. WT-1 is required for early kidney development. *Cell* 1993; 74: 679–91.
47. Hammes A, Guo JK, Lutsch G, Leheste JR, Landrock D, Ziegler U, Gubler MC, Schedl A. Two splice variants of the Wilms' tumor 1 gene have distinct functions during sex determination and nephron formation. *Cell* 2001; 106: 319–29.
48. Shimamura R, Fraizer GC, Trapman J, Lau Yfc, Saunders GF. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor. *Clin Cancer Res* 1997; 3: 2571–80.
49. Miyamoto Y, Taniguchi H, Hamel F, Silversides DW, Viger RS. A GATA4/WT1 cooperation regulates transcription of genes required for mammalian sex determination and differentiation. *BMC Mol Biol* 2008; 9: 44.
50. Viger RS, Mertineit C, Trasler JM, Nemer M. Transcription factor GATA-4 is expressed in a sexually dimorphic pattern during mouse gonadal development and is a potent activator of the

- Müllerian inhibiting substance promoter. *Development* 1998; 125: 2665–75.
51. Tevosian SG, Albrecht KH, Crispino JD, Fujiwara Y, Eicher EM, Orkin SH. Gonadal differentiation, sex determination and normal Sry expression in mice require direct interaction between transcription partners GATA4 and FOG2. *Development* 2002; 129: 4627–34.
 52. Nef S, Verma-Kurvari S, Merenmies J, Vassalli J-D, Efstratiadis A, Accili D, Parada LF. Testis determination requires insulin receptor family function in mice. *Nature* 2003; 426: 291–5.
 53. Luo X, Ikeda Y, Parker KL. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. *Cell* 1994; 77: 481–90.
 54. Miyamoto N, Yoshida M, Kuratani S, Matsuo I, Aizawa S. Defects of urogenital development in mice lacking *Emx2*. *Development* 1997; 124: 1653–64.
 55. Birk OS, Casiano DE, Wassif CA, Cogliati T, Zhao L, Zhao Y, Grinberg A, Huang S, Kreidberg JA, Parker KL, Porter FD, Westphal H. The LIM homeobox gene *Lhx9* is essential for mouse gonad formation. *Nature* 2000; 403: 909–13.
 56. Kent J, Wheatley SC, Andrews JE, Sinclair AH, Koopman P. A male-specific role for SOX9 in vertebrate sex determination. *Development* 1996; 122: 2813–22.
 57. Foster JW, Dominguez-Steglich MA, Guioli S, Kwok C, Weller PA, Stevanovi M, Weissenbach J, Mansour S, Young ID, Goodfellow PN. Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. *Nature* 1994; 372: 525–30.
 58. Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, Pasantes J, Bricarelli FD, Keutel J, Hustert E, Wolf U, Tommerup N, Schempff W, Scherer G. Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. *Cell* 1994; 79: 1111–20.
 59. Chaboissier M-C, Kobayashi A, Vidal VIP, Lützkendorf S, van de Kant HJG, Wegner M, de Rooij DG, Behringer RR, Schedl A. Functional analysis of *Sox8* and *Sox9* during sex determination in the mouse. *Development* 2004; 131: 1891–901.
 60. Barrionuevo F, Bagheri-Fam S, Klattig J, Kist R, Taketo MM, Englert C, Scherer G. Homozygous inactivation of *Sox9* causes complete XY sex reversal in mice. *Biol Reprod* 2006; 74: 195–201.
 61. Vidal VP, Chaboissier MC, de Rooij DG, Schedl A. *Sox9* induces testis development in XX transgenic mice. *Nat Genet* 2001; 28: 216–7.
 62. Bishop CE, Whitworth DJ, Qin Y, Agoulnik AI, Agoulnik IU, Harrison WR, Behringer RR, Overbeek PA. A transgenic insertion upstream of *sox9* is associated with dominant XX sex reversal in the mouse. *Nat Genet* 2000; 26: 490–4.
 63. Sekido R, Lovell-Badge R. Sex determination involves synergistic action of SRY and SF1 on a specific *Sox9* enhancer. *Nature* 2008; 453: 930–4.
 64. Colvin JS, Green RP, Schmahl J, Capel B, Ornitz DM. Male-to-female sex reversal in mice lacking fibroblast growth factor 9. *Cell* 2001; 104: 875–89.
 65. Schmahl J, Kim Y, Colvin JS, Ornitz DM, Capel B. *Fgf9* induces proliferation and nuclear localization of FGFR2 in Sertoli precursors during male sex determination. *Development* 2004; 131: 3627–36.
 66. Kim Y, Kobayashi A, Sekido R, DiNapoli L, Brennan J, Chaboissier M-C, Poulat F, Behringer RR, Lovell-Badge R, Capel B. *Fgf9* and *Wnt4* act as antagonistic signals to regulate mammalian sex determination. *PLoS Biol* 2006; 4: e187.
 67. Parma P, Radi O, Vidal V, Chaboissier MC, Dellambra E, Valentini S, Guerra L, Schedl A, Camerino G. R-spondin1 is essential in sex determination, skin differentiation and malignancy. *Nat Genet* 2006; 38: 1304–9.
 68. Vainio S, Heikkilä M, Kispert A, Chin N, McMahon AP. Female development in mammals is regulated by Wnt-4 signalling. *Nature* 1999; 397: 405–9.
 69. Chassot A-A, Ranc F, Gregoire EP, Roepers-Gajadien HL, Taketo MM, Camerino G, de Rooij DG, Schedl A, Chaboissier M-C. Activation of beta-catenin signaling by *Rspo1* controls differentiation of the mammalian ovary. *Hum Mol Genet* 2008; 17: 1264–77.
 70. Tomizuka K, Horikoshi K, Kitada R, Sugawara Y, Iba Y, Kojima A, Yoshitome A, Yamawaki K, Amagai M, Inoue A, Oshima T, Kakitani M. R-spondin1 plays an essential role in ovarian development through positively regulating Wnt-4 signaling. *Hum Mol Genet* 2008; 17: 1278–91.
 71. Maatouk DM, DiNapoli L, Alvers A, Parker KL, Taketo MM, Capel B. Stabilization of beta-catenin in XY gonads causes male-to-female sex-reversal. *Hum Mol Genet* 2008; 17: 2949–55.
 72. Orth JM. Proliferation of Sertoli cells in fetal and postnatal rats: a quantitative autoradiographic study. *Anat Rec* 1982; 203: 485–92.
 73. Burgoyne PS, Buehr M, Koopman P, Rossant J, McLaren A. Cell-autonomous action of the testis-determining gene: Sertoli cells are exclusively XY in XX-XY chimaeric mouse testes. *Development* 1988; 102: 443–50.
 74. Schmahl J, Eicher EM, Washburn LL, Capel B. Sry induces cell proliferation in the mouse gonad. *Development* 2000; 127: 65–73.
 75. Palmer SJ, Burgoyne PS. In situ analysis of fetal, prepubertal and adult XX-XY chimaeric mouse testes: Sertoli cells are predominantly, but not exclusively, XY. *Development* 1991; 112: 265–8.
 76. Wilhelm D, Martinson F, Bradford S, Wilson MJ, Combes AN, Beverdam A, Bowles J, Mizusaki H, Koopman P. Sertoli cell differentiation is induced both cell-autonomously and through prostaglandin signaling during mammalian sex determination. *Dev Biol* 2005; 287: 111–24.
 77. Wilhelm D, Hiramatsu R, Mizusaki H, Widjaja L, Combes AN, Kanai Y, Koopman P. SOX9 regulates prostaglandin D synthase gene transcription in vivo to ensure testis development. *J Biol Chem* 2007; 282: 10553–60.
 78. Moniot B, Declosmenil F, Barrionuevo F, Scherer G, Aritake K, Malki S, Marzi L, Cohen-Solal A, Georg I, Klattig J, Englert C, Kim Y, Capel B, Eguchi N, Urade Y, Boizet-Bonhoure B, Poulat F. The PGD2 pathway, independently of FGF9, amplifies SOX9 activity in Sertoli cells during male sexual differentiation. *Development* 2009; 136: 1813–21.
 79. Gao F, Maiti S, Alam N, Zhang Z, Deng JM, Behringer RR, Lécureuil C, Guillou F, Huff V. The Wilms tumor gene, *Wt1*, is required for *Sox9* expression and maintenance of tubular architecture in the developing testis. *Proc Natl Acad Sci USA* 2006; 103: 11987–92.
 80. Dadhich RK, Real FM, Zurita F, Barrionuevo FJ, Burgos M, Jiménez R. Role of apoptosis and cell proliferation in the testicular dynamics of seasonal breeding mammals: a study in the Iberian mole, *Talpa occidentalis*. *Biol Reprod* 2010; 83: 83–91.
 81. Barrionuevo F, Georg I, Scherthan H, Lécureuil C, Guillou F, Wegner M, Scherer G. Testis cord differentiation after the sex determination stage is independent of *Sox9* but fails in the combined absence of *Sox9* and *Sox8*. *Dev Biol* 2009; 327: 301–12.
 82. O'Bryan MK, Takada S, Kennedy CL, Scott G, Harada S-i, Ray MK, Dai Q, Wilhelm D, de Kretser DM, Eddy EM, Koopman P, Mishina Y. *Sox8* is a critical regulator of adult Sertoli cell function and male fertility. *Dev Biol* 2008; 316: 359–70.

83. Chang H, Gao F, Guillou F, Taketo MM, Huff V, Behringer RR. Wt1 negatively regulates beta-catenin signaling during testis development. *Development* 2008; 135: 1875–85.
84. Pesce M, Wang X, Wolgemuth DJ, Schöler H. Differential expression of the Oct-4 transcription factor during mouse germ cell differentiation. *Mech Dev* 1998; 71: 89–98.
85. Kocer A, Reichmann J, Best D, Adams IR. Germ cell sex determination in mammals. *Mol Hum Reprod* 2009; 15: 205–13.
86. Bowles J, Knight D, Smith C, Wilhelm D, Richman J, Mamiya S, Yashiro K, Chawengsaksohak K, Wilson MJ, Rossant J, Hamada H, Koopman P. Retinoid signaling determines germ cell fate in mice. *Science* 2006; 312: 596–600.
87. Koubova J, Menke DB, Zhou Q, Capel B, Griswold MD, Page DC. Retinoic acid regulates sex-specific timing of meiotic initiation in mice. *Proc Natl Acad Sci USA* 2006; 103: 2474–9.
88. Baltus AE, Menke DB, Hu Y-C, Goodheart ML, Carpenter AE, de Rooij DG, Page DC. In germ cells of mouse embryonic ovaries, the decision to enter meiosis precedes premeiotic DNA replication. *Nat Genet* 2006; 38: 1430–4.
89. Menke DB, Koubova J, Page DC. Sexual differentiation of germ cells in XX mouse gonads occurs in an anterior-to-posterior wave. *Dev Biol* 2003; 262: 303–12.
90. MacLean G, Li H, Metzger D, Chambon P, Petkovich M. Apoptotic extinction of germ cells in testes of Cyp26b1 knockout mice. *Endocrinology* 2007; 148: 4560–7.
91. Geijsen N, Horoschak M, Kim K, Gribnau J, Eggan K, Daley GQ. Derivation of embryonic germ cells and male gametes from embryonic stem cells. *Nature* 2004; 427: 148–54.
92. Nayernia K, Lee JH, Drusenheimer N, Nolte J, Wulf G, Dressel R, Gromoll J, Engel W. Derivation of male germ cells from bone marrow stem cells. *Lab Invest* 2006; 86: 654–63.
93. White JC, Highland M, Kaiser M, Clagett-Dame M. Vitamin A deficiency results in the dose-dependent acquisition of anterior character and shortening of the caudal hindbrain of the rat embryo. *Dev Biol* 2000; 220: 263–84.
94. Tahayato A, Dollé P, Petkovich M. Cyp26C1 encodes a novel retinoic acid-metabolizing enzyme expressed in the hindbrain, inner ear, first branchial arch and tooth buds during murine development. *Gene Expr Patterns* 2003; 3: 449–54.
95. Kumar S, Chatzi C, Brade T, Cunningham TJ, Zhao X, Duester G. Sex-specific timing of meiotic initiation is regulated by Cyp26b1 independent of retinoic acid signalling. *Nat Commun* 2011; 2: 151.
96. Bowles J, Feng C-W, Spiller C, Davidson T-L, Jackson A, Koopman P. FGF9 suppresses meiosis and promotes male germ cell fate in mice. *Dev Cell* 2010; 19: 440–9.
97. Ottolenghi C, Pelosi E, Tran J, Colombino M, Douglass E, Nedorezov T, Cao A, Forabosco A, Schlessinger D. Loss of Wnt4 and Foxl2 leads to female-to-male sex reversal extending to germ cells. *Hum Mol Genet* 2007; 16: 2795–804.
98. Benton L, Shan LX, Hardy MP. Differentiation of adult Leydig cells. *J Steroid Biochem Mol Biol* 1995; 53: 61–8.
99. Habert R, Lejeune H, Saez JM. Origin, differentiation and regulation of fetal and adult Leydig cells. *Mol Cell Endocrinol* 2001; 179: 47–74.
100. Yao HH-C, Whoriskey W, Capel B. Desert Hedgehog/Patched 1 signaling specifies fetal Leydig cell fate in testis organogenesis. *Genes Dev* 2002; 16: 1433–40.
101. Park SY, Tong M, Jameson JL. Distinct roles for steroidogenic factor 1 and desert hedgehog pathways in fetal and adult Leydig cell development. *Endocrinology* 2007; 148: 3704–10.
102. Basciani S, Mariani S, Arizzi M, Ulisse S, Rucci N, Jannini EA, Della Rocca C, Manicone A, Carani C, Spera G, Gnassi L. Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-alpha and -beta during human testicular development and disease. *J Clin Endocrinol Metab* 2002; 87: 2310–9.
103. Gnassi L, Basciani S, Mariani S, Arizzi M, Spera G, Wang C, Bondjers C, Karlsson L, Betsholtz C. Leydig cell loss and spermatogenic arrest in platelet-derived growth factor (PDGF)-A-deficient mice. *J Cell Biol* 2000; 149: 1019–26.
104. Olaso R, Pairault C, Habert R. Expression of type I and II receptors for transforming growth factor beta in the adult rat testis. *Histochem Cell Biol* 1998; 110: 613–8.
105. Sarraj MA, Chua HK, Umbers A, Loveland KL, Findlay JK, Stenvers KL. Differential expression of TGFBR3 (betaglycan) in mouse ovary and testis during gonadogenesis. *Growth Factors* 2007; 25: 334–45.
106. Sarraj MA, Escalona RM, Umbers A, Chua HK, Small C, Griswold M, Loveland K, Findlay JK, Stenvers KL. Fetal testis dysgenesis and compromised Leydig cell function in Tgfb3 (beta glycan) knockout mice. *Biol Reprod* 2010; 82: 153–62.
107. Cupp AS, Kim G, Skinner MK. Expression and action of transforming growth factor beta (TGFbeta1, TGFbeta2, and TGFbeta3) during embryonic rat testis development. *Biol Reprod* 1999; 60: 1304–13.
108. Memon MA, Anway MD, Covert TR, Uzumcu M, Skinner MK. Transforming growth factor beta (TGFbeta1, TGFbeta2 and TGFbeta3) null-mutant phenotypes in embryonic gonadal development. *Mol Cell Endocrinol* 2008; 294: 70–80.
109. Clark AM, Garland KK, Russell LD. Desert hedgehog (Dhh) gene is required in the mouse testis for formation of adult-type Leydig cells and normal development of peritubular cells and seminiferous tubules. *Biol Reprod* 2000; 63: 1825–38.
110. Jiménez R, Burgos M, Sánchez A, Sinclair AH, Alarcón FJ, Marín JJ, Ortega E, Díaz de la Guardia R. Fertile females of the mole *Talpa occidentalis* are phenotypic intersexes with ovotestes. *Development* 1993; 118: 1303–11.
111. Patek CE, Kerr JB, Gosden RG, Jones KW, Hardy K, Muggleton-Harris AL, Handyside AH, Whittingham DG, Hooper ML. Sex chimaerism, fertility and sex determination in the mouse. *Development* 1991; 113: 311–25.
112. Barsoum IB, Bingham NC, Parker KL, Jorgensen JS, Yao HH-C. Activation of the Hedgehog pathway in the mouse fetal ovary leads to ectopic appearance of fetal Leydig cells and female pseudohermaphroditism. *Dev Biol* 2009; 329: 96–103.
113. Josso N, Cate RL, Picard JY, Vigier B, di Clemente N, Wilson C, Imbeaud S, Pepinsky RB, Guerrier D, Boussin L. Anti-müllerian hormone: the Jost factor. *Recent Prog Horm Res* 1993; 48: 1–59.
114. Behringer RR, Finegold MJ, Cate RL. Müllerian-inhibiting substance function during mammalian sexual development. *Cell* 1994; 79: 415–25.
115. Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, Cate RL, Behringer RR. Genetic analysis of the Müllerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. *Genes Dev* 1996; 10: 2577–87.
116. De Santa Barbara P, Bonneaud N, Boizet B, Desclozeaux M, Moniot B, Sudbeck P, Scherer G, Poulat F, Berta P. Direct interaction of SRY-related protein SOX9 and steroidogenic factor 1 regulates transcription of the human anti-Müllerian hormone gene. *Mol Cell Biol* 1998; 18: 6653–65.

117. Arango NA, Lovell-Badge R, Behringer RR. Targeted mutagenesis of the endogenous mouse *Mis* gene promoter: in vivo definition of genetic pathways of vertebrate sexual development. *Cell* 1999; 99: 409–19.
118. Schepers G, Wilson M, Wilhelm D, Koopman P. SOX8 is expressed during testis differentiation in mice and synergizes with SF1 to activate the *Amh* promoter in vitro. *J Biol Chem* 2003; 278: 28101–8.
119. Sock E, Schmidt K, Hermanns-Borgmeyer I, Bösl MR, Wegner M. Idiopathic weight reduction in mice deficient in the high-mobility-group transcription factor Sox8. *Mol Cell Biol* 2001; 21: 6951–9.

Received May 23, 2011; accepted September 16, 2011